



The treatment of metastatic non-small cell lung cancer in a new era of personalized medicine

Vera Hirsh*

Department of Medical Oncology, McGill University Health Centre, Montreal, QC, Canada

*Correspondence: vera.hirsh@muhc.mcgill.ca

Edited and reviewed by:

Stephen V. Liu, Georgetown University, USA

Keywords: NSCLC, personalized medicine, lung cancer, NSCLC treatment, supportive care

Lung cancer is the leading cause of cancer-related mortality in Canada (1) and around the world. Non-small cell lung cancer (NSCLC) is the most frequent form of lung cancer, accounting for approximately 87% of cases and the majority of these are metastatic at the time of presentation (2, 3).

We have reached a plateau (4, 5) with different systemic chemotherapies, specifically platinum-based, which have been used to treat metastatic NSCLC for several decades; median survival improved to 8–10 months (from 4–6 months without treatment). Significant toxicities limited the number of cycles that could be administered (6).

Current recommendations for first-line treatment of advanced NSCLC use both histologic and molecular diagnostics in designing the course of treatment (7, 8). We have learned the importance of distinguishing between squamous and non-squamous histologies (9) in order to choose an appropriate chemotherapy regimen. The algorithms for first-line treatment of advanced NSCLC recommend using both histologic and molecular diagnostics in designing the treatment (7, 10, 11). This in turn requires an adequate amount of biopsied tumor tissue in order to be able to perform all the necessary testing, which is needed for right decisions (12). Tumor aspirations for the diagnosis are not acceptable anymore.

Recent advances in understanding signaling pathways for malignant cells, interconnections in those pathways, the importance of various receptors (13–15), and biomarkers, and also the interplay between various oncogenes have led to the development of targeted treatments that are improving not only the efficacy of the treatments, but also safety benefits, less toxicity (16) with improvement of patient's quality of life (17) in this palliative setting.

These treatments are aimed at specific (especially genetic) alterations in the malignant cells. Various NSCLC subtypes are associated with potentially targetable biomarkers such as mutation of the epidermal growth factor receptors (EGFR) (18–22), KRAS (23), or the presence of echinoderm microtubule-associated protein-like 4 (EML-4) and anaplastic lymphoma kinase (ALK) fusion genes, ALK rearrangements (13, 15). C-Met over-expression or amplification (24–27), are playing a role in the development of resistance to the therapies (28), i.e., with EGFR-TKIs. T790M mutation on Exon 20 in the EGFR domain is the most frequent cause of the development of this resistance (29).

Knowledge about the advantages of treatments with targeted agents in advanced NSCLC is rapidly growing, but the hope is to eventually apply this knowledge to earlier stages of NSCLC and

thus to increase the cure rate of these patients. Combining various targeted agents or sequencing them properly will be of the utmost importance in the new era of personalized targeted therapy (30). Many clinical trials are ongoing to help us make the appropriate decisions how to optimally treat advanced NSCLC in future (31, 32). Immunotherapy of advanced NSCLC (33) is one of the exciting areas of research and results of phase III trials are eagerly awaited.

Contributors in this issue of *Frontiers in Thoracic Oncology* describe the importance of team work (34) from diagnosis through various treatments to supportive care. They explain and emphasize the importance of the treatments of brain metastases (35) and bone metastases with new bone targeted agents (36). Management of adverse events when the new targeted agents are used (16) and analysis of patients' health-related quality of life (HR QOL) (17) and the impact on patients' performance status (PS) are also discussed in this issue. It is very important to preserve a good PS of patients in order to make it possible for them to receive multiple lines of the treatments now available for advanced NSCLC.

Our review will cover the description starting with the interventional procedures (12), to treatments delivered by radiation oncologists (37), medical oncologists (10, 11, 34), including descriptions of ongoing trials to provide a glimpse of the future (31, 32). The importance of early supportive care (38), which should be an integral part of active care from the start of treatment of advanced NSCLC, will also be discussed.

We hope to provide a complete review of present and future approaches to personalized medicine in advanced NSCLC, reflecting the present views, and practices in Canada.

ACKNOWLEDGMENTS

We would like to thank the following sponsors for their support: Major sponsors: Boehringer-Ingelheim, Eli Lilly, and Roche, other sponsors: MERCK, Astra Zeneca, and Pfizer. We would also like to thank Stavroula Kalantzis for her kind secretarial support with this Research Topic, who not only helped both myself and Dr. Melosky but also many other authors in this issue.

REFERENCES

1. Canadian Cancer Society's Steering Committee. *Canadian Cancer Statistics 2010*. Toronto, ON: Canadian Cancer Society (2010).
2. United States, National Institutes of Health, National Cancer Institute (NCI). *Non-Small Cell Lung Cancer Treatment (PDQ)*. Bethesda, MD: Health professional version (2010). Available from: <http://www.cancer.gov/cancertopics/pdq/treatment/non-small-cell-lung/healthprofessional>

3. Pisters KM, Evans WK, Azzoli CG, Kris MG, Smith CA, Desch CE, et al. Cancer care Ontario and American society of clinical oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I – IIIA resectable non-small cell lung cancer guideline. *J Clin Oncol* (2007) **25**:5506–18. doi:10.1200/JCO.2007.14.1226
4. Cagle PT, Allen TC, Dacic S, Beasley MB, Borczuk AC, Chirieac LR, et al. Revolution in lung cancer: new challenges for the surgical pathologist. *Arch Pathol Lab Med* (2011) **135**:110–6. doi:10.1043/2010-0567-RA.1
5. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. *N Engl J Med* (2002) **346**:92–8. doi:10.1056/NEJMoa011954
6. Cagle PT, Dacic S. Lung cancer and the future of pathology. *Arch Pathol Lab Med* (2011) **135**:293–5. doi:10.1043/2011.0037-ED.1
7. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. *J Clin Oncol* (2008) **26**:3543–51. doi:10.1200/JCO.2007.15.0375
8. Brega E, Brandao G. Non-small cell lung carcinoma biomarker testing: the pathologist's perspective. *Front Oncol* (2014) **4**:182. doi:10.3389/fonc.2014.00182
9. Blais N, Hirsh V. Chemotherapy in metastatic NSCLC – new regimens (pemetrexed, nab-paclitaxel). *Front Oncol* (2014) **4**:177. doi:10.3389/fonc.2014.00177
10. Al-Farsi A, Ellis PM. Treatment paradigms for patients with metastatic non-small cell lung cancer, squamous lung cancer: first, second, and third-line. *Front Oncol* (2014) **4**:157. doi:10.3389/fonc.2014.00157
11. Melosky B. Treatment algorithms for patients with metastatic non-small cell, non-squamous lung cancer. *Front Oncol* (2014) **4**:256. doi:10.3389/fonc.2014.00256
12. Ofiara LM, Navasakulpong A, Beaudoin S, Gonzalez AV. Optimizing tissue sampling for the diagnosis, subtyping, and molecular analysis of lung cancer. *Front Oncol* (2014) **4**:253. doi:10.3389/fonc.2014.00253
13. Korpanty GJ, Graham DM, Vincent MD, Leighl NB. Biomarkers that currently affect clinical practice in lung cancer: EGFR, ALK, MET, ROS-1, and KRAS. *Front Oncol* (2014) **4**:204. doi:10.3389/fonc.2014.00204
14. Melosky B. Review of EGFR TKIs in metastatic NSCLC, including ongoing trials. *Front Oncol* (2014) **4**:244. doi:10.3389/fonc.2014.00244
15. Esfahani K, Agulnik JS, Cohen V. A systemic review of resistance mechanisms and ongoing clinical trials in ALK-rearranged non-small cell lung cancer. *Front Oncol* (2014) **4**:174. doi:10.3389/fonc.2014.00174
16. Melosky B, Hirsh V. Management of common toxicities in metastatic NSCLC related to anti-lung cancer therapies with EGFR-TKIs. *Front Oncol* (2014) **4**:238. doi:10.3389/fonc.2014.00238
17. Hirsh V. Is the evaluation of quality of life in NSCLC trials important? Are the results to be trusted? *Front Oncol* (2014) **4**:173. doi:10.3389/fonc.2014.00173
18. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med* (2004) **350**:2129–39. doi:10.1056/NEJMoa040938
19. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science* (2004) **304**:1497–500. doi:10.1126/science.1099314
20. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proc Natl Acad Sci USA* (2004) **101**:13306–11. doi:10.1073/pnas.0405220101
21. Li AR, Chitale D, Riely GJ, Pao W, Miller VA, Zakowski MF, et al. EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. *J Mol Diagn* (2008) **10**:242–8. doi:10.2353/jmol.2008.070178
22. Uramoto H, Mitsudomi T. Which biomarker predicts benefit from EGFR – TKI treatment for patients with lung cancer? *Br J Cancer* (2007) **96**:857–63. doi:10.1038/sj.bjc.6603665
23. Sartori G, Cavazza A, Sgambato A, Marchioni A, Barbieri F, Longo L, et al. EGFR and K-*ras* mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors. *Am J Clin Pathol* (2009) **131**:478–89. doi:10.1309/AJCPH0TRMPXVZW2F
24. Ma PC, Tretiakova MS, MacKinnon AC, Ramnath N, Johnson C, Dietrich S, et al. Expression and mutational analysis of MET in human solid cancers. *Genes Chromosomes Cancer* (2008) **47**:1025–37. doi:10.1002/gcc.20604
25. Okuda K, Sasaki H, Yukiue H, Yano M, Fujii Y. MET gene copy number predicts the prognosis for completely resected non-small cell lung cancer. *Cancer Sci* (2008) **99**:2280–5. doi:10.1111/j.1349-7006.2008.00916.x
26. Lutterbach B, Zeng Q, Davis LJ, Hatch H, Hang G, Kohl NE, et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. *Cancer Res* (2007) **67**:2081–8. doi:10.1158/0008-5472.CAN-06-3495
27. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ErbB3 signaling. *Science* (2007) **316**:1039–43. doi:10.1126/science.1141478
28. Spaans JN, Goss GD. Trials to overcome drug resistance to EGFR and ALK targeted therapies – past, present, and future. *Front Oncol* (2014) **4**:233. doi:10.3389/fonc.2014.00233
29. Spaans JN, Goss GD. Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer. *Front Oncol* (2014) **4**:190. doi:10.3389/fonc.2014.00190
30. Blais N, Kassouf E. Maintenance therapies for non-small cell lung cancer. *Front Oncol* (2014) **4**:213. doi:10.3389/fonc.2014.00213
31. Zer A, Leighl N. Promising targets and current clinical trials in metastatic non-squamous NSCLC. *Front Oncol* (2014) **4**:329. doi:10.3389/fonc.2014.00329
32. Vincent MD. Promising targets and current clinical trials in metastatic squamous cell lung cancer. *Front Oncol* (2014) **4**:320. doi:10.3389/fonc.2014.00320
33. Mostafa AA, Morris DG. Immunotherapy for lung cancer: has it finally arrived? *Front Oncol* (2014) **4**:288. doi:10.3389/fonc.2014.00288
34. Dawe DE, Ellis PM. The treatment of metastatic non-small cell lung cancer in the elderly: an evidence-based approach. *Front Oncol* (2014) **4**:178. doi:10.3389/fonc.2014.00178
35. Owen S, Souhami L. The management of brain metastases in non-small cell lung cancer. *Front Oncol* (2014) **4**:248. doi:10.3389/fonc.2014.00248
36. Hirsh V. Targeted treatments of bone metastases in patients with lung cancer. *Front Oncol* (2014) **4**:146. doi:10.3389/fonc.2014.00146
37. Faria SL. Role of radiotherapy in metastatic non-small cell lung cancer. *Front Oncol* (2014) **4**:229. doi:10.3389/fonc.2014.00229
38. Howe M, Burkes RL. Collaborative care in NSCLC: the role of early palliative care. *Front Oncol* (2014) **4**:192. doi:10.3389/fonc.2014.00192

Conflict of Interest Statement: The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 02 December 2014; accepted: 16 January 2015; published online: 03 February 2015.

Citation: Hirsh V (2015) The treatment of metastatic non-small cell lung cancer in a new era of personalized medicine. *Front. Oncol.* 5:20. doi: 10.3389/fonc.2015.00020
This article was submitted to Thoracic Oncology, a section of the journal *Frontiers in Oncology*.

Copyright © 2015 Hirsh. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.